@article{Aurore Perrot_Hélène Monjanel_Réda Bouabdallah_Philippe Quittet_Clémentine Sarkozy_Marc Bernard_Aspasia Stamatoullas_Cécile Borel_Krimo Bouabdallah_Emmanuelle Nicolas-Virelizier_Marion Fournier_Franck Morschhauser_Pauline Brice_2016, place={Pavia, Italy}, title={Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program}, volume={101}, url={https://haematologica.org/article/view/7682}, DOI={10.3324/haematol.2015.134213}, abstractNote={Brentuximab vedotin was reported to be effective and safe against refractory/relapsed Hodgkin lymphoma in cohorts of between 12 to 102 patients. Herein we report our retrospective analysis of the French experience with brentuximab vedotin used alone to treat 240 refractory/relapsed Hodgkin lymphoma patients enrolled in a named patient program between 2011 and 2013. All patients had histologically documented CD30+ Hodgkin lymphoma; 74% had refractory disease or early relapses. After a median of 3 lines of chemotherapy, brentuximab vedotin was infused intravenously (1.8 mg/kg every 3 weeks). The primary endpoint was best response. Response at the end of treatment, its duration, survival data and toxicity profile were secondary endpoints. Patients received a median of 6 cycles; 68 underwent a consolidation thereafter. The best response was observed after a median of 4 cycles in 145 (60.4%) patients: 33.8% complete response/unconfirmed complete response, 26.7% partial response. Objective responses were observed as decreased (39.3%) in the 28 patients >60 years. The median response duration was 8.4 months. With median follow-up at 16.1 months, median progression-free survival was 6.8 months and this was significantly longer for patients transplanted after brentuximab vedotin (a median of 18,8 months); median overall survival was not reached. No death has been linked to brentuximab vedotin toxicity. The most common adverse events were peripheral sensory neuropathy (29.3%) and hematological toxicity. The results of this analysis support the previously reported brentuximab vedotin efficacy with manageable toxicity. Because of the short-term responses in most patients, a high-dose therapy with stem cell transplantation for responders should be considered as quickly as possible.}, number={4}, journal={Haematologica}, author={Aurore Perrot and Hélène Monjanel and Réda Bouabdallah and Philippe Quittet and Clémentine Sarkozy and Marc Bernard and Aspasia Stamatoullas and Cécile Borel and Krimo Bouabdallah and Emmanuelle Nicolas-Virelizier and Marion Fournier and Franck Morschhauser and Pauline Brice}, year={2016}, month={Mar.}, pages={466-473} }